Phase 2 Head and Neck Cancer Trial, Recruiting (NCT05952934)

Phase 2 Head and Neck Cancer Trial, Recruiting NCT05952934 Sponsor: University of Arkansas Condition: Head and Neck Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05952934 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Head And Neck Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are able to give informed consent to participate
People who are 18 years of age or older, male or female
People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, and who have completed curative treatment — such as surgery, radiation, chemotherapy, or immunotherapy — within the 120 days before the screening visit
People who have no signs of remaining cancer, confirmed by clinical and imaging assessments
People who are willing and able to follow the requirements of the study protocol

Who may not be able to join:

Women of childbearing potential who have a positive urine pregnancy test
People who are pregnant or trying to become pregnant during the study period
Women who are breastfeeding or plan to breastfeed during the study period
People who have a known allergy to Candin® (the study treatment)
People whose treating doctors or study investigators believe it would not be in their best interest to join or continue in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Omar Atiq, University of Arkansas

Phone: 501-686-8274

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05952934

Sponsor: University of Arkansas

Phase: Phase 2

Status: Recruiting

Condition: Head and Neck Cancer

Trial contact: 501-686-8274

More information: https://clinicaltrials.gov/study/NCT05952934

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are able to give informed consent to participate
People who are 18 years of age or older, male or female
People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, and who have completed curative treatment — such as surgery, radiation, chemotherapy, or immunotherapy — within the 120 days before the screening visit
People who have no signs of remaining cancer, confirmed by clinical and imaging assessments
People who are willing and able to follow the requirements of the study protocol

Who may not be able to join:

Women of childbearing potential who have a positive urine pregnancy test
People who are pregnant or trying to become pregnant during the study period
Women who are breastfeeding or plan to breastfeed during the study period
People who have a known allergy to Candin® (the study treatment)
People whose treating doctors or study investigators believe it would not be in their best interest to join or continue in the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of Arkansas

Registry

ClinicalTrials.gov

Start date

12 February 2024

Est. completion

31 July 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assessment of clinical efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov